MedMira (Germany) Performance
| 47M Stock | EUR 0.08 0 4.08% |
On a scale of 0 to 100, MedMira holds a performance score of 6. The company secures a Beta (Market Risk) of 1.18, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MedMira will likely underperform. Please check MedMira's semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to make a quick decision on whether MedMira's current price movements will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in MedMira are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, MedMira reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -69.7 K |
MedMira |
MedMira Relative Risk vs. Return Landscape
If you would invest 6.45 in MedMira on November 2, 2024 and sell it today you would earn a total of 1.20 from holding MedMira or generate 18.6% return on investment over 90 days. MedMira is currently producing 0.726% returns and takes up 9.5232% volatility of returns over 90 trading days. Put another way, 84% of traded stocks are less volatile than MedMira, and 86% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
MedMira Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedMira's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MedMira, and traders can use it to determine the average amount a MedMira's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0762
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 47M | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.52 actual daily | 84 84% of assets are less volatile |
Expected Return
| 0.73 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average MedMira is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MedMira by adding it to a well-diversified portfolio.
MedMira Fundamentals Growth
MedMira Stock prices reflect investors' perceptions of the future prospects and financial health of MedMira, and MedMira fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MedMira Stock performance.
| Return On Asset | -0.23 | |||
| Profit Margin | (2.27) % | |||
| Operating Margin | (1.79) % | |||
| Current Valuation | 34.88 M | |||
| Shares Outstanding | 697.45 M | |||
| Price To Sales | 29.64 X | |||
| Revenue | 952.13 K | |||
| EBITDA | (1.07 M) | |||
| Cash And Equivalents | 20.61 K | |||
| Total Debt | 40 K | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.88 M) | |||
| Total Asset | 3.83 M | |||
About MedMira Performance
By analyzing MedMira's fundamental ratios, stakeholders can gain valuable insights into MedMira's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MedMira has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MedMira has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, the Asia Pacific, and internationally. The company was founded in 1993 and is headquartered in Halifax, Canada. MEDMIRA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange.Things to note about MedMira performance evaluation
Checking the ongoing alerts about MedMira for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MedMira help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MedMira is way too risky over 90 days horizon | |
| MedMira has some characteristics of a very speculative penny stock | |
| MedMira appears to be risky and price may revert if volatility continues | |
| MedMira has high likelihood to experience some financial distress in the next 2 years | |
| MedMira has accumulated 40 K in total debt. MedMira has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MedMira until it has trouble settling it off, either with new capital or with free cash flow. So, MedMira's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MedMira sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MedMira to invest in growth at high rates of return. When we think about MedMira's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 952.13 K. Net Loss for the year was (1.83 M) with loss before overhead, payroll, taxes, and interest of (512.51 K). | |
| MedMira has accumulated about 20.61 K in cash with (1.88 M) of positive cash flow from operations. | |
| Roughly 70.0% of the company shares are owned by insiders or employees |
- Analyzing MedMira's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MedMira's stock is overvalued or undervalued compared to its peers.
- Examining MedMira's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MedMira's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MedMira's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MedMira's stock. These opinions can provide insight into MedMira's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MedMira Stock analysis
When running MedMira's price analysis, check to measure MedMira's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedMira is operating at the current time. Most of MedMira's value examination focuses on studying past and present price action to predict the probability of MedMira's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedMira's price. Additionally, you may evaluate how the addition of MedMira to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |